

Motoo Nagane

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2403139/publications.pdf>

Version: 2024-02-01

40
papers

1,708
citations

471061

17
h-index

454577

30
g-index

40
all docs

40
docs citations

40
times ranked

2448
citing authors

#	ARTICLE	IF	CITATIONS
1	12p gain is predominantly observed in non-germinomatous germ cell tumors and identifies an unfavorable subgroup of central nervous system germ cell tumors. <i>Neuro-Oncology</i> , 2022, 24, 834-846.	0.6	16
2	Transcriptome and methylome analysis of CNS germ cell tumor finds its cell-of-origin in embryogenesis and reveals shared similarities with testicular counterparts. <i>Neuro-Oncology</i> , 2022, 24, 1246-1258.	0.6	14
3	Phase I/II study of tirabrutinib, a second-generation Brutonâ€™s tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. <i>Neuro-Oncology</i> , 2021, 23, 122-133.	0.6	102
4	So-called bifocal tumors with diabetes insipidus and negative tumor markers: are they all germinoma?. <i>Neuro-Oncology</i> , 2021, 23, 295-303.	0.6	24
5	Survival in patients with glioblastoma at a first progression does not correlate with <i>IDH1</i> gene mutation status. <i>Japanese Journal of Clinical Oncology</i> , 2021, 51, 45-53.	0.6	16
6	Necessity for craniospinal irradiation of germinoma with positive cytology without spinal lesion on MR imagingâ€”A controversy. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab086.	0.4	7
7	Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). <i>Neuro-Oncology</i> , 2021, 23, 1056-1071.	0.6	68
8	TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. <i>Acta Neuropathologica</i> , 2021, 142, 323-338.	3.9	58
9	Efficacy and safety of nivolumab in Japanese patients with first recurrence of glioblastoma: an open-label, non-comparative study. <i>International Journal of Clinical Oncology</i> , 2021, 26, 2205-2215.	1.0	6
10	Liquid biopsy of cerebrospinal fluid for <i>MYD88</i> L265P mutation is useful for diagnosis of central nervous system lymphoma. <i>Cancer Science</i> , 2021, 112, 4702-4710.	1.7	16
11	Is using intracerebral hemorrhage scoring systems valid for mortality prediction in surgically treated patients?. <i>Neurosurgical Review</i> , 2021, 44, 2747-2753.	1.2	2
12	Low tumor cell content predicts favorable prognosis in germinoma patients. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab110.	0.4	8
13	Safety and efficacy of depatuxizumab mafodotin in Japanese patients with malignant glioma: A nonrandomized, phase 1/2 trial. <i>Cancer Science</i> , 2021, 112, 5020-5033.	1.7	19
14	A Hyperactive RelA/p65-Hexokinase 2 Signaling Axis Drives Primary Central Nervous System Lymphoma. <i>Cancer Research</i> , 2020, 80, 5330-5343.	0.4	19
15	Genetic analysis in patients with newly diagnosed glioblastomas treated with interferon-beta plus temozolomide in comparison with temozolomide alone. <i>Journal of Neuro-Oncology</i> , 2020, 148, 17-27.	1.4	5
16	Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2020, 50, 999-1008.	0.6	4
17	Frontotemporal dermoid cyst with incomplete dermal sinus tract in an adult: A case report. , 2020, 11, 429.		4
18	Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium. <i>Neuro-Oncology</i> , 2019, 21, 1565-1577.	0.6	74

#	ARTICLE	IF	CITATIONS
19	Detection of t(14;18)(q32;q21) for IgH/ BCL 2 in central nervous system tumor-like lesions with chronic perivascular inflammation. <i>Clinical and Experimental Neuroimmunology</i> , 2019, 10, 244-258.	0.5	0
20	Alterations in ALK/ROS1/NTRK/MET drive a group of infantile hemispheric gliomas. <i>Nature Communications</i> , 2019, 10, 4343.	5.8	200
21	Reduced Neoantigen Expression Revealed by Longitudinal Multiomics as a Possible Immune Evasion Mechanism in Glioma. <i>Cancer Immunology Research</i> , 2019, 7, 1148-1161.	1.6	56
22	COT-03 EVALUATING FUNCTIONING AND DISABILITY OF A PATIENT WITH BRAIN TUMOR BY WHODAS. <i>Neuro-Oncology Advances</i> , 2019, 1, ii41-ii41.	0.4	0
23	NQPC-06 FUNCTIONAL OUTCOMES OF INITIAL TREATMENTS FOR PATIENTS WITH PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA ASSESSED BY ADL AND NEUROCOGNITIVE FUNCTION. <i>Neuro-Oncology Advances</i> , 2019, 1, ii30-ii30.	0.4	0
24	NQPC-07 IMMEDIATE POSTOPERATIVE REHABILITATION FOR PATIENTS WITH NEWLY-DIAGNOSED GLIOMA. <i>Neuro-Oncology Advances</i> , 2019, 1, ii31-ii31.	0.4	0
25	NI-22 IMPROVED DELINEATION OF THE SUPERFICIAL CEREBRAL VENOUS SYSTEM IN BRAIN CT ANGIOGRAPHY BY ULTRAHIGH-RESOLUTION CT FOR ASSISTING BRAIN TUMOR SURGERY. <i>Neuro-Oncology Advances</i> , 2019, 1, ii29-ii29.	0.4	0
26	MyD88 Mutation in Elderly Predicts Poor Prognosis in Primary Central Nervous System Lymphoma: Multi-Institutional Analysis. <i>World Neurosurgery</i> , 2018, 112, e69-e73.	0.7	26
27	GENE-33. MECHANISM OF ACQUIRED MUTATION AFTER TMZ TREATMENT. <i>Neuro-Oncology</i> , 2018, 20, vi110-vi110.	0.6	0
28	ACTR-48. FEASIBILITY OF DISCONTINUATION OF ADJUVANT TEMOZOLOMIDE AFTER 12 CYCLES REMAINING WITHOUT PROGRESSION FOR PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi22-vi22.	0.6	0
29	CSIG-31. MUTATION OF PIM1 GENE IN PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA INHIBITS CELL DEATH THROUGH CHANGE IN SUBCELLULAR LOCALIZATION OF PIM-1 AND INCREASE OF BAD PHOSPHORYLATION. <i>Neuro-Oncology</i> , 2018, 20, vi49-vi50.	0.6	0
30	IMMU-58. REDUCED NEOANTIGEN EXPRESSION AS A POSSIBLE IMMUNE EVASION MECHANISM DURING GLIOMA PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi134-vi134.	0.6	0
31	Genome-wide methylation profiles in primary intracranial germ cell tumors indicate a primordial germ cell origin for germinomas. <i>Acta Neuropathologica</i> , 2017, 133, 445-462.	3.9	64
32	Prognostic factors for primary central nervous system lymphomas treated with high-dose methotrexate-based chemo-radiotherapy. <i>Japanese Journal of Clinical Oncology</i> , 2017, 47, 925-934.	0.6	8
33	Distinct molecular profile of diffuse cerebellar gliomas. <i>Acta Neuropathologica</i> , 2017, 134, 941-956.	3.9	40
34	Genomic characterization of primary central nervous system lymphoma. <i>Acta Neuropathologica</i> , 2016, 131, 865-875.	3.9	138
35	Nimotuzumab enhances temozolomide-induced growth suppression of glioma cells expressing mutant <i>EGFR</i> in vivo. <i>Cancer Medicine</i> , 2016, 5, 486-499.	1.3	26
36	Recurrent neomorphic mutations of MTOR in central nervous system and testicular germ cell tumors may be targeted for therapy. <i>Acta Neuropathologica</i> , 2016, 131, 889-901.	3.9	70

#	ARTICLE	IF	CITATIONS
37	Prolonged and severe thrombocytopenia with pancytopenia induced by radiation-combined temozolomide therapy in a patient with newly diagnosed glioblastoma—analysis of O ⁶ -methylguanine-DNA methyltransferase status. <i>Journal of Neuro-Oncology</i> , 2009, 92, 227-232.	1.4	18
38	Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. <i>Journal of Neurosurgery</i> , 2001, 95, 472-479.	0.9	74
39	The Enhanced Tumorigenic Activity of a Mutant Epidermal Growth Factor Receptor Common in Human Cancers Is Mediated by Threshold Levels of Constitutive Tyrosine Phosphorylation and Unattenuated Signaling. <i>Journal of Biological Chemistry</i> , 1997, 272, 2927-2935.	1.6	502
40	Application of Antisense Ribonucleic Acid Complementary to O ⁶ -Methylguanine-deoxyribonucleic Acid Methyltransferase Messenger Ribonucleic Acid for Therapy of Malignant Gliomas. <i>Neurosurgery</i> , 1997, 41, 434-441.	0.6	24